STOCK TITAN

Exelixis (EXEL) shareholder files Form 144 to sell 3,856 shares on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Exelixis Inc. has a shareholder planning to sell restricted shares under Rule 144. The notice covers 3,856 shares of Exelixis common stock to be sold through UBS Financial Services on NASDAQ, with an approximate aggregate market value of $165,383.84. These shares were acquired as restricted stock units from the issuer on 01/05/2026, the same date listed as the payment date. The filing also reports that Exelixis had 259,708,689 shares of common stock outstanding, providing context for the size of this planned sale.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for EXEL disclose?

The Form 144 discloses a planned sale of 3,856 Exelixis common shares under Rule 144. The shares were acquired as restricted stock units and will be sold on NASDAQ through UBS Financial Services, with an aggregate market value of $165,383.84.

How many EXEL shares are planned to be sold under this Form 144?

The filing covers a proposed sale of 3,856 shares of Exelixis common stock. These shares are to be sold on NASDAQ via UBS Financial Services and were originally acquired as restricted stock units from the issuer on 01/05/2026.

What is the approximate value of the EXEL shares in this Rule 144 notice?

The Form 144 lists an aggregate market value of $165,383.84 for the 3,856 Exelixis common shares. This value reflects the estimated market price of the shares to be sold through UBS Financial Services on NASDAQ.

When were the EXEL shares being sold under Form 144 acquired?

The Exelixis shares were acquired on 01/05/2026 as a restricted stock unit grant from the issuer. The filing also shows 01/05/2026 as the date of payment, with the nature of payment described as N/A, consistent with equity compensation.

On which exchange will the EXEL Form 144 shares be sold?

The planned sale of 3,856 Exelixis common shares is listed for execution on the NASDAQ exchange. UBS Financial Services, based at 11 Madison Avenue in New York, is named as the broker handling the transaction for this Rule 144 notice.

How many EXEL shares were outstanding compared to the Form 144 amount?

The filing reports 259,708,689 Exelixis common shares outstanding at the time of the notice. The planned Rule 144 sale of 3,856 shares is small relative to this total, offering context on the scale of the proposed transaction.
Exelixis Inc

NASDAQ:EXEL

EXEL Rankings

EXEL Latest News

EXEL Latest SEC Filings

EXEL Stock Data

11.41B
261.54M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
ALAMEDA